NASDAQ:GEMP - Gemphire Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.77 +0.27 (+1.15 %) (As of 02/17/2020 07:12 AM ET) Add Compare Today's Range$21.00Now: $23.77▼$26.2750-Day Range$0.30MA: $8.81▼$23.5052-Week Range$0.24Now: $23.77▼$1.49Volume48,306 shsAverage Volume116,318 shsMarket Capitalization$353.46 millionP/E RatioN/ADividend YieldN/ABeta2.82 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GEMP Previous Symbol CUSIPN/A CIK1638287 Webhttp://www.gemphire.com/ Phone734-245-1700Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick Ratio0.67Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book44.02Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-23,640,000.00 Net MarginsN/A Return on Equity-419.70% Return on Assets-173.05%Miscellaneous Employees9 Outstanding Shares14,870,000Market Cap$353.46 million Next Earnings DateN/A OptionableOptionable Receive GEMP News and Ratings via Email Sign-up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GEMP Rates by TradingView Gemphire Therapeutics (NASDAQ:GEMP) Frequently Asked Questions What is Gemphire Therapeutics' stock symbol? Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP." How were Gemphire Therapeutics' earnings last quarter? Gemphire Therapeutics Inc (NASDAQ:GEMP) announced its earnings results on Friday, March, 15th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.15. View Gemphire Therapeutics' Earnings History. What is the consensus analysts' recommendation for Gemphire Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gemphire Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gemphire Therapeutics. Has Gemphire Therapeutics been receiving favorable news coverage? Media coverage about GEMP stock has been trending somewhat positive recently, according to InfoTrie. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gemphire Therapeutics earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Gemphire Therapeutics. Who are some of Gemphire Therapeutics' key competitors? Some companies that are related to Gemphire Therapeutics include BELLUS Health (BLUSF), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), IGM Biosciences (IGMS), Intra-Cellular Therapies (ITCI), Supernus Pharmaceuticals (SUPN), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Revance Therapeutics (RVNC), Phibro Animal Health (PAHC), Endonovo Therapeutics (ENDV), NextCure (NXTC), Portola Pharmaceuticals (PTLA), Myovant Sciences (MYOV) and Opko Health (OPK). What other stocks do shareholders of Gemphire Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gemphire Therapeutics investors own include Anavex Life Sciences (AVXL), Progenics Pharmaceuticals (PGNX), Pixelworks (PXLW), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Nektar Therapeutics (NKTR), Protalix Biotherapeutics (PLX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO) and Melinta Therapeutics (MLNT). Who are Gemphire Therapeutics' key executives? Gemphire Therapeutics' management team includes the folowing people: Dr. Charles L. Bisgaier, Co-Founder, Chairman & Chief Scientific Officer (Age 65)Dr. Steven R. Gullans, CEO, Pres, Director, Principal Financial Officer & Principal Accounting Officer (Age 66)Mr. Seth Reno, Chief Commercial Officer (Age 52)Mr. Jeffrey S. Mathiesen C.P.A., CPA, Consultant (Age 58)Ms. Amy Zaremba Rabourn, Director of Fin. When did Gemphire Therapeutics IPO? (GEMP) raised $30 million in an initial public offering (IPO) on Friday, August 5th 2016. The company issued 3,000,000 shares at $10.00 per share. Jefferies and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers. How do I buy shares of Gemphire Therapeutics? Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Gemphire Therapeutics' stock price today? One share of GEMP stock can currently be purchased for approximately $23.77. How big of a company is Gemphire Therapeutics? Gemphire Therapeutics has a market capitalization of $353.46 million. Gemphire Therapeutics employs 9 workers across the globe.View Additional Information About Gemphire Therapeutics. What is Gemphire Therapeutics' official website? The official website for Gemphire Therapeutics is http://www.gemphire.com/. How can I contact Gemphire Therapeutics? Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700 or via email at [email protected] MarketBeat Community Rating for Gemphire Therapeutics (NASDAQ GEMP)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 279 (Vote Outperform)Underperform Votes: 241 (Vote Underperform)Total Votes: 520MarketBeat's community ratings are surveys of what our community members think about Gemphire Therapeutics and other stocks. Vote "Outperform" if you believe GEMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEMP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2020 by MarketBeat.com StaffFeatured Article: Why is cost of goods sold important?
